Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism APOL1 inhibitors(Apolipoprotein L1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Maze Therapeutics, Inc.Startup |
Active Organization Maze Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Kidney Diseases | Preclinical | US | Maze Therapeutics, Inc.Startup | 18 Nov 2022 |